重酒石酸氢可酮(Hydrocodone bitartrate) - 药物靶点：Opioid receptors_在研适应症：疼痛_专利_临床

概要

基本信息

简介Hydrocodone bitartrate是一种阿片类止痛药，通常被称为“氢可酮”。其化学名为4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) 或morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5)。氢可酮是美国用于急性和慢性疼痛的最常用药物，2012年的处方量超过1.35亿。由于其易获取性和滥用模式，氢可酮被认为是引起滥用和误用的阿片类药物的主要驱动力。其机制是通过刺激阿片受体发挥镇痛作用。

药物类型

小分子化药

别名

酒石酸氢可酮、AFI-001、ATLP-03

+ [9]

靶点

Opioid receptors

作用方式

激动剂

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

疼痛

非在研适应症

慢性骨关节炎慢性疼痛药物滥用+ [3]

原研机构-

在研机构

Purdue Pharma LP

非在研机构

Teva Branded Pharmaceutical Products R&D, Inc.

Societal CDMO Gainesville LLC

Zogenix, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2013-10-25),

疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29NO10

InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N

CAS号34195-34-1

关联

32

项与重酒石酸氢可酮相关的临床试验

NCT06780202

/ Recruiting临床2期IIT

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.
The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

开始日期2025-01-27

申办/合作机构

Emory University

NCT06585163

/ Not yet recruiting临床1期

A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers

This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.

开始日期2024-09-01

申办/合作机构

Quivive Pharma, Inc.初创企业

[+1]

NCT06232577

/ Active, not recruiting临床2期IIT

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

开始日期2024-03-27

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与重酒石酸氢可酮相关的临床结果

登录后查看更多信息

100 项与重酒石酸氢可酮相关的转化医学

登录后查看更多信息

100 项与重酒石酸氢可酮相关的专利（医药）

登录后查看更多信息

1,113

项与重酒石酸氢可酮相关的文献（医药）

2025-04-03·Drug metabolism and personalized therapy

Prolonged post-operative hydrocodone usage due to psychotropic drug interaction

Article

作者: Roach, Abbey R. ; Gaskins, Jeremy T. ; Malkani, Arthur L. ; Karimi, Viana F. ; Whitt, Aaron G. ; Yakkanti, Madhusudhan R. ; Hartley, Brandi ; Renfrow, Ruby E. ; Jortani, Saeed A.

Abstract:

Objectives:

To explore pain outcomes in patients prescribed hydrocodone and psychotropic medications with or without CYP2D6 inhibition activity.

Methods:

Patients hospitalized for lower/limited upper extremity injuries who were prescribed hydrocodone alongside a psychotropic medication were considered for this study (n=224). A subset of these patients (n=178) was prescribed a psychotropic medication known to inhibit CYP2D6, while the remainder (n=46) were prescribed psychotropic medications without CYP2D6 inhibition activity. Patient demographics and pain outcomes were collected by electronic health record review and interviews.

Results:

Patients taking a psychotropic inhibitor of CYP2D6 exhibited longer duration of opioid use post-discharge (median 33 days [IQR 10–99]) compared with patients taking a psychotropic non-inhibitor (4 days [2–20], p<0.001). No significant differences were observed with in-hospital pain outcomes, including total dose of hydrocodone administered, duration of hydrocodone use, pain index scores, and the occurrence of common mild/moderate/severe hydrocodone side effects.

Conclusions:

Patients prescribed at least one psychotropic inhibitor of CYP2D6 were more likely to continue using hydrocodone for up to 3 months following surgery. Knowledge of these critical drug-drug interactions could enhance clinical practice and improve patient outcomes. This study highlights negative post-operative pain outcomes in patients prescribed hydrocodone alongside a psychotropic inhibitor of CYP2D6. The results of this study indicate that patients taking psychotropic medications that inhibit CYP2D6 are at increased risk for prolonged hydrocodone use following orthopedic surgery.

2025-04-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Synergistic topical cancer therapy using dual drug delivery of dexamethasone and 5-fluorouracil via deoxycholic acid micelle-carboxymethyl cellulose hydrogel composites

Article

作者: Pourmanoucheri, Zahra ; Jalal, Twana Jamal ; Rezvanfar, Arefeh ; Behbood, Leila ; Hosseinzadeh, Leila ; Ranjbar, Sedigheh ; Rasekhian, Mahsa

Topical formulations containing 5-Fluorouracil (5-FU) have been proven effective in preventing the proliferation of skin cancer cells. However, their use is linked to side effects such as inflammatory and allergic reactions. Dexamethasone (Dexa) is a synthetic glucocorticoid used across allergic reactions which can be useful in preventing the 5-FU side effects. This study aims to introduce 5-FU loaded deoxycholic acid micelles (DCA Mics) incorporated into carboxymethyl cellulose hydrogel matrix (CMC Hyd) containing Dexa to design Mic/Hyd based carriers cross-linked by physical and chemical cross-linker. The release of 5-FU and Dexa from the final formulation at pH of 5.5 was around 55 % after 5 h. The final formulation shows the pH-controlled release by crosslinking CMC Hyd, increasing the release of Dexa at physiological pH. The MTT results showed both Hyd and the synthesized Mics were non-toxic, but the toxicity increased significantly when 5-FU was incorporated into the formulation. 5-FU@Mic (IC50 = 5.5 μg/mL) was observed to be more potent cytotoxic against A431 compared to the free drugs 5-FU (IC50 = 17.5 μg/mL), and final formulation (IC50 = 26 μg/mL). The dual drug delivery systems might provide insights into the potential of pre-exposure of Dexa for mitigating inflammation caused by 5-FU.

2025-04-01·JOURNAL OF ETHNOPHARMACOLOGY

Haizao Yuhu decoction ameliorates silica-induced lung injury by inhibiting transforming growth factor-beta1/Smad pathway

Article

作者: Xie, Linshen ; Bao, Qixue ; Wang, Mengzhu ; Xu, Yunyi ; Qian, Rui ; Wang, Liqun ; Chen, Xuxi ; Yao, Yuqin ; Zhang, Luoning

ETHNOPHARMACOLOGICAL RELEVANCE:

Haizao Yuhu Decoction (HYD) is a traditional Chinese herbal formula known for regulating Qi and dispersing stasis.

AIM OF THE STUDY:

This study investigates the effects of HYD on silica-induced lung injury and the underlying mechanisms.

MATERIALS AND METHODS:

The main constituents of HYD were identified using ultra-performance liquid chromatography Q-Exactive mass spectrometry (UPLC-QE-MS). Network pharmacology was employed to predict the targets and pathways through which HYD ameliorates silicosis, which were validated in a silica-induced lung injury mouse model and a TGF-β1-induced alveolar epithelial cell model. Pathological evaluation was conducted using hematoxylin-eosin (H&E) and Masson staining, while inflammatory cytokines and fibrosis were assessed via enzyme-linked immunosorbent assay (ELISA) and hydroxyproline quantification. Western blotting (WB) was performed to analyse protein expression levels of targeted markers. Proliferation and migration capabilities of MLE12 cells treated with HYD and its bioactive constituents (glycitein, diosmetin, and limonin) were assessed using cell counting kit-8 (CCK-8) and wound healing assays.

RESULTS:

HYD significantly alleviated silica-induced lung injury, reducing inflammatory response and collagen deposition. A total of 176 constituents were identified in HYD, with 111 being pharmacologically active and linked to 1397 potential therapeutic targets, 107 associated with silicosis. Enrichment analyses highlighted the TGF-β1/Smad pathway and epithelial-mesenchymal transition (EMT) in HYD's anti-silicosis effects, which was validated by the restoration of TGF-β1, p-Smad2/Smad2, p-Smad3/Smad3, E-cadherin, and Vimentin following HYD treatment. Additionally, glycitein, diosmetin, and limonin inhibited the proliferation and migration of TGF-β1-induced MLE12 cells and suppressed the activation of TGF-β1/Smad pathway and EMT.

CONCLUSIONS:

HYD effectively alleviates silica-induced lung injury by specifically inhibiting the TGF-β1/Smad pathway and EMT process.

55

项与重酒石酸氢可酮相关的新闻（医药）

2025-04-10

·PRNewswire

Newborn Brains Are Smaller When Exposed to Opioids During Gestation

An important "first dive" into data from the 4-site Outcomes of Babies with Opioid Exposure (OBOE) study features a Cincinnati Children's expert as co-first author CINCINNATI, April 10, 2025 /PRNewswire/ -- When pregnant women take opioids during pregnancy, even opioids such as buprenorphine or methadone to treat opioid use disorder, the developing brains of their children can be significantly affected, according to a study published April 7, 2025, in JAMA Pediatrics. Continue Reading Antenatal opioid exposure is associated with smaller neonatal brain volumes, with varying impact depending on the type and number of exposures, according to research published in JAMA Pediatrics. Stephanie Merhar, MD, MS, at Cincinnati Children's was first co-author. Total brain volume was nearly 5% smaller among 173 newborns with antenatal opioid exposure compared to 96 unexposed newborns, based on magnetic resonance imaging (MRI) scans. More specifically, reduced volumes among opioid-exposed newborns occurred in cortical gray matter, deep gray matter, white matter, cerebellum, brainstem, and the right and left amygdala. There were notable differences in the location and scale of the effects, which varied depending on the type of opioid involved, and whether other drugs were also taken during pregnancy. "We have known for a while that children exposed to opioids during pregnancy are at risk of later developmental and behavioral problems, but it was hard to know whether that was due to the opioids themselves or other factors such as other exposures or lower birth weight," says co-first author Stephanie Merhar, MD, MS, a neonatologist at Cincinnati Children's. "This study was launched because we needed a large study where we were able to control for things like nicotine exposure and birth weight. Our next step is to follow the children in the study to see whether having smaller brain volumes in the newborn period affects later development and behavior." The double-threat opioids pose to mothers and children Nearly 1 in 12 newborns in the United States in 2020 – or about 300,000 infants – were exposed to alcohol, opioids, marijuana or cocaine before they were born, according to the Substance Abuse and Mental Health Services Administration (SAMHSA). Prenatal substance exposure in rural areas often exceeds overall national averages. Opioids include illegal drugs like heroin and fentanyl, prescription drugs like oxycodone and hydrocodone, and medications for opioid use disorder like buprenorphine and methadone. Opioid use often goes hand in hand with smoking and use of other substances such as alcohol and marijuana. This study compared newborns born to mothers who took opioids only and newborns born to mothers who used other substances as well as opioids. Newborns exposed to opioids plus other substances had smaller brain volumes in more regions compared to those exposed to opioids only. The most common opioids among participants in the new study were buprenorphine (68.8%) and methadone (26%). Both of these opioids are routinely used to treat opioid use disorder (OUD) and are both recommended for treatment of OUD during pregnancy by the American College of Obstetricians and Gynecologists. "We know that buprenorphine and methadone are life-saving medications for women with OUD," Merhar says. "We don't want to imply that women with OUD should wean off these medications, but we agree with the ACOG recommendation for more research on medically supervised withdrawal in pregnant women." The study was praised in an accompanying editorial penned by Nethra Madurai, MD, and Lauren Jantzie, PhD, both of Johns Hopkins University School of Medicine. Other small studies have shown fetal brain changes caused by opioids. But this multi-center study is the first to be large enough to convincingly distinguish effects linked to opioids versus confounding factors such as maternal smoking, birth weight, education levels. The study authors "present compelling evidence of the direct effects of opioids on the developing brain," the editorial states. "Given the prospective design of the trial, they account for other postnatal factors…allowing us to dispel previous uncertainty surrounding the direct impacts of opioids on the brain vs the confounding effects of other environmental factors." What's next? Having more precise information about the affected parts of the brain could allow scientists to focus on interventions to support healthy brain development for children born after opioid exposure. "Indeed, we must shift our focus beyond the initial withdrawal symptoms associated with POE [prenatal opioid exposure] if we are to improve the lifelong health and well-being of infants and children impacted by the opioid epidemic," the editorial states. Read more about Merhar's research related to opioid exposure: 'Eat, Sleep, Console' Approach Slashes ICU Stays for Opioid-Exposed Newborns In Utero Opioid Exposure Impacts Fetal Brain Size and Development $8M Grant Funds Long-Term Opioid Exposure Study SOURCE Cincinnati Children's Hospital Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-04-07

·PRNewswire

Elysium Therapeutics Announces Development of Overdose Rescue Technology Specifically Designed for Oral Fentanyl

Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) targets an unmet challenge in the illicit opioid crisis as current rescue medications are not designed for synthetic opioids, including oral fentanyl. LYONS, Colo., April 7, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, announced its plan to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology. The company has completed in vivo proof-of-concept studies and expects to file an Investigational New Drug (IND) application in 2026. SOOPR is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone prodrug formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 to 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. "Fentanyl overdoses often require very high, or repeated, doses of short-acting opioid antagonists to effect a successful rescue," said Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics. "Unfortunately, many who overdose face a rapid recurrence of symptoms, known as re-narcotization, which can lead to respiratory depression and increase the likelihood of hypoxic brain injury or death. SOOPR is designed to address this situation, and Elysium is now focused on advancing its development as a potential first-ever, faster-onset, longer-acting opioid rescue therapy specifically intended to treat fentanyl overdose." Currently approved short-acting opioid antagonists like Narcan and Opvee® were designed to effectively counteract overdoses from opioids such as heroin and oxycodone. However, these rescue agents are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. According to reports from multiple state-affiliated health agencies, 31 to 39% of fentanyl overdose decedents had been administered naloxone.2 Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus naloxone (Narcan) and a significantly longer duration of action. This profile is especially useful in counteracting oral fentanyl overdoses associated with prolonged fentanyl absorption and exposure that often outlast the short-acting profile of Narcan. "In designing SOOPR, Elysium recognized that synthetic opioids – now the number one killer of adults aged 18 to 45 in the U.S. – are particularly lethal," said Tom Jenkins, Ph.D., Co-Founder and Chief Scientific Officer of Elysium Therapeutics. "Patients initially treated with a rapid-acting, long-duration reversal agent, such as SOOPR, are expected to have less risk of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Further, rescue interventions with SOOPR are expected to require less intensive monitoring in both the ambulance and emergency department and increase the likelihood of survival. Additionally, SOOPR is designed to be delivered by intramuscular injection, either using a pre-filled syringe or autoinjector, which has been demonstrated to be more rapid and predictable than intranasal delivery in urgent settings, where every second counts." "In addition to preventing overdose deaths from recreational, illicit use, the Department of Defense (DOD) has made clear the importance of improving opioid overdose rescue as a needed medical countermeasure," added Sturmer. "The DOD reported that the availability of synthetic opioids, such as fentanyl and its derivatives, represents a significant threat as a chemical weapon, which could be easily disseminated as a weapon of mass destruction into air, water or food supplies, putting countless lives at risk. We look forward to working with defense and government organizations as we develop SOOPR as a tool to prevent injury and death in these worrisome scenarios." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . 1 Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88 (Also see footnotes 8, 9, and 10 for additional discussion). 2 Watson, W.A., Steele, M.T., Muelleman, R.L., Rush, M.D., 1998. Opioid toxicity recurrence after an initial response to naloxone. J. Toxicol. Clin. Toxicol. 36 (1-2), 11–17. . SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-03-11

·新药前沿

疼痛领域First In Class药物刚获FDA批准，Best In Class就来了

今年1月30日Vertex Pharmaceuticals公司开发的NaV1.8抑制剂Journavx (suzetrigine) 获得美国FDA批准，成为20多年来首款治疗急性疼痛的First In Class新药。 Journavx或许仅仅是开启了疼痛领域的一个新时代。竞争对手Latigo Biotherapeutics公司一直对外宣称，其开发的NaV1.8抑制剂LTG-001有潜力成为Best In Class。 Latigo于2020年创立，针对经遗传验证的疼痛靶点开发非阿片类药物的治疗药物。2024年2月，Latigo完成1.35亿美元的A轮融资。巧合的是，Latigo该轮融资宣布也是在竞争对手Vertex公布Journavx（VEX-548）的III期数据两周后。在两项III期试验中，VX-548虽然达到了0至48小时疼痛强度显著降低的主要终点，但却没有达到一个关键的次要终点——优于Vicodin（氢可酮/对乙酰氨基酚），而且分析师还对该药在另一个次要终点上的表现提出了质疑：疼痛缓解的中位时间。Vertex公司报告说，VX-548的起效时间比安慰剂 “更快达到有意义的疼痛缓解”，腹部整形术后患者的中位疼痛缓解时间为2小时，拇囊切除术患者的中位疼痛缓解时间为4小时，而安慰剂组为8小时。而Latigo当时正在进行LTG-001的I期试验有可能迅速起效。该公司认为，VX-548的起效时间“可能并不完全是靶点的特征……部分原因可能是化合物的特殊性，我们希望我们化合物的特殊性能加快起效时间”。 Latigo公司临时首席执行官Desmond Padhi表示，其团队相信LTG-001有可能成为同类产品中的佼佼者（Best In Class）。“我们非常重视确保我们的化合物在适当的组织中获得最佳的生物分布......在靶点表达的外周神经系统中，尽量减少在靶点不表达的组织（中枢神经系统）中的暴露”。已完成的I期临床试验在72名健康受试者的结果表明，LTG-00的耐受性良好，吸收迅速，Tmax约为1.5小时。而suzetrigine的Tmax约为3小时。今年1月，LTG-00正式开启II期试验（NCT06774625），不过Latigo是否会对Vertex构成挑战仍然有待观察。值得一提的是，今年3月3日，LTG-001治疗急性疼痛还被FDA授予快速通道认定（FTD）。而在国内，NaV1.8抑制剂也是制药企业竞争的疼痛热门靶点之一。延伸阅读：恒瑞急性疼痛新药HRS-2129获批临床，布局新一代NaV1.8抑制剂，兵贵神速本文由「新药前沿」微信公众号根据公开资料整理编辑，欢迎个人转发至朋友圈。媒体或机构转载授权请在「新药前沿」微信公众号留言公众号名称，审核通过后开通白名单获取转载授权，转载请标识来源。免责声明：本文仅作信息交流之目的，非投资建议或者治疗方案推荐，「新药前沿」微信公众号不对任何主体因使用本文内容而导致的任何损失承担责任。限于作者水平和专业知识所限，如有谬误，欢迎指正！

快速通道临床2期临床3期临床结果

100 项与重酒石酸氢可酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重酒石酸氢可酮	R05DA03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Societal CDMO Gainesville LLC	2013-10-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2010-11-01
慢性疼痛	临床3期	美国	Zogenix, Inc.	2010-05-01
腰痛	临床3期	美国	Zogenix, Inc.	2010-03-01
慢性骨关节炎	临床2期	-	Zogenix, Inc.	2002-09-01
药物滥用	临床1期	美国	Cephalon, Inc.	2012-03-01
药物滥用	临床1期	加拿大	Cephalon, Inc.	2012-03-01
终末期肾脏病	临床1期	美国	Cephalon, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2018	N/A	-	-	Opioid (Total Hip Replacement (THR))	構製簾鹹壓廠鏇齋構範(鏇繭膚範艱構糧窪鏇繭) = 範憲壓築鏇積願醖蓋鹽蓋蓋鑰獵淵顧鏇顧觸蓋 (艱夢選繭醖簾選積鏇繭 ) 更多	-	2018-10-22
				Opioid (Total Knee Replacement (TKR))	構製簾鹹壓廠鏇齋構範(鏇繭膚範艱構糧窪鏇繭) = 餘鑰網範齋遞憲鹹製膚蓋蓋鑰獵淵顧鏇顧觸蓋 (艱夢選繭醖簾選積鏇繭 ) 更多
NCT01402375 (CTgov)	临床3期	急性疼痛 \| 四肢损伤	720	Hydrocodone (first trial) (Hydrocodone (First Trial))	範觸製網蓋鏇構衊膚遞(鹹製築積築鹹顧鹹齋鬱) = 膚獵網醖襯鹽膚艱窪齋窪齋淵範糧製製獵獵齋 (淵範憲壓範獵蓋觸鹽夢, 1.7) 更多	-	2018-05-01
				Codeine (first trial) (Codeine (First Trial))	範觸製網蓋鏇構衊膚遞(鹹製築積築鹹顧鹹齋鬱) = 蓋鏇壓糧壓蓋齋選觸衊窪齋淵範糧製製獵獵齋 (淵範憲壓範獵蓋觸鹽夢, 1.8) 更多
NCT01240863 (CTgov)	临床3期	腰痛 \| 骨关节炎 \| 慢性疼痛	391	Placebo (Placebo (Double-blind Treatment Period))	繭醖膚夢餘糧鹽夢襯壓(願鑰鹽齋簾鏇艱憲獵製) = 憲鑰蓋壓鏇蓋廠膚壓願簾襯襯窪範範齋遞憲蓋 (鏇廠鑰餘膚願選構製鏇, 0.169) 更多	-	2017-06-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	繭醖膚夢餘糧鹽夢襯壓(願鑰鹽齋簾鏇艱憲獵製) = 糧齋觸壓廠繭憲鏇鑰網簾襯襯窪範範齋遞憲蓋 (鏇廠鑰餘膚願選構製鏇, 0.176) 更多
NCT01922739 (CTgov)	临床3期	腰痛	182	Placebo+Hydrocodone ER	醖窪憲醖觸繭選餘繭糧 = 選淵構膚憲觸醖願襯構襯簾糧鏇構醖觸蓋衊遞 (顧齋築衊醖憲艱鹽選窪, 繭範遞廠積選襯衊窪願 ~ 衊廠齋淵襯範襯淵鹹鬱) 更多	-	2017-06-02
NCT01789970 (CTgov)	临床3期	腰痛	625	Placebo (Placebo (Double-blind Treatment Period))	膚選鹹膚繭窪網廠鹽範(製鬱餘廠襯顧餘積齋網) = 鑰襯鏇選網艱顧築網膚遞遞積蓋壓淵廠範構壓 (選襯窪糧膚遞窪觸壓繭, 0.145) 更多	-	2017-04-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	膚選鹹膚繭窪網廠鹽範(製鬱餘廠襯顧餘積齋網) = 構顧遞鏇網鑰艱廠憲鏇遞遞積蓋壓淵廠範構壓 (選襯窪糧膚遞窪觸壓繭, 0.134) 更多
NCT01517295 (CTgov)	临床4期	慢性疼痛	30	Hydrocodone (Group 1)	製壓廠襯壓淵窪鹹構鹽(糧糧繭窪醖醖衊襯鏇鑰) = 顧築膚選膚鬱艱願餘襯鏇遞範鏇築獵壓艱膚糧 (積蓋膚蓋艱襯憲遞蓋獵, 0) 更多	-	2016-07-28
				Hydrocodone (Group 2)	製壓廠襯壓淵窪鹹構鹽(糧糧繭窪醖醖衊襯鏇鑰) = 積構齋憲鬱製獵築窪鬱鏇遞範鏇築獵壓艱膚糧 (積蓋膚蓋艱襯憲遞蓋獵, 0) 更多
NCT01859715 (CTgov)	N/A	药物相互作用	502	Oxycodone (Oxycodone Group)	鹽顧觸壓窪齋艱觸艱艱(願膚鬱願窪願築範鏇獵) = 鏇醖壓膚鏇膚窪窪蓋積憲艱構淵遞製餘繭網窪 (憲襯齋艱鑰鬱醖壓積製, 蓋獵網獵窪鬱遞鹹餘醖 ~ 觸淵淵構網餘蓋壓齋鏇) 更多	-	2016-05-05
				Hydrocodone (Hydrocodone/Acetaminophen Group)	鹽顧觸壓窪齋艱觸艱艱(願膚鬱願窪願築範鏇獵) = 範憲艱廠築願窪築選鑰憲艱構淵遞製餘繭網窪 (憲襯齋艱鑰鬱醖壓積製, 鬱願顧襯簾衊繭觸蓋獵 ~ 鹹餘醖襯範簾餘醖簾襯) 更多
NCT01452529 (CTgov)	临床3期	腰痛	905	Hydrocodone bitartrate q24h film-coated tablets (Hydrocodone Bitartrate)	遞廠顧夢壓艱顧壓築艱(製鏇鏇範顧網餘鬱淵憲) = 顧壓構網廠製選廠製築鏇願窪願膚夢繭鏇繭簾 (製蓋積壓構鬱襯築範選, 0.13) 更多	-	2014-12-04
				Placebo to match hydrocodone bitartrate q24h tablets (Placebo)	遞廠顧夢壓艱顧壓築艱(製鏇鏇範顧網餘鬱淵憲) = 壓蓋製網願網獵願餘簾鏇願窪願膚夢繭鏇繭簾 (製蓋積壓構鬱襯築範選, 0.13) 更多
NCT01400139 (CTgov)	临床3期	慢性疼痛	922	Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate (HYD Core Study)	積齋膚醖獵夢願鏇簾獵 = 鏇網選鏇製選壓簾築壓網鑰廠襯築範遞廠獵構 (遞餘鏇廠製壓憲襯襯壓, 範襯醖醖襯積醖顧廠夢 ~ 鑰選醖簾窪製築觸蓋顧) 更多	-	2014-12-04
				Hydrocodone bitartrate (HYD)+Hydrocodone bitartrate (HYD Extension Period)	積齋膚醖獵夢願鏇簾獵 = 鏇獵衊構網壓憲積夢範網鑰廠襯築範遞廠獵構 (遞餘鏇廠製壓憲襯襯壓, 遞壓襯鏇範積網範築齋 ~ 鹹壓鏇鬱製淵網鹹鏇獵) 更多
NCT01115569 (CTgov)	临床3期	慢性疼痛	424	Hydrocodone Bitartrate (Open-label Hydrocodone Bitartrate Extended Release Capsules)	範鏇艱鹹醖膚襯積選鹽(願鹹製艱顧築築鏇襯醖) = 鑰簾夢範齋鹽艱蓋鏇築窪獵衊壓蓋糧構壓鏇獵 (繭鑰鬱蓋願築網鏇醖鹽, 2.2)	-	2014-04-25
				Hydrocodone Bitartrate Extended Release (HC-ER)+Hydrocodone Bitartrate (Conversion/Titration Phase)	鏇餘構蓋淵觸鹹蓋夢餘(鑰範積鹽憲網網膚夢糧) = 顧廠憲範獵襯鬱衊襯顧簾簾築壓範願鏇鹹範淵 (網積簾構衊繭鏇積膚製, 積鏇糧淵簾鏇衊選築蓋 ~ 壓醖蓋鏇選構願鬱繭簾) 更多